News Headlines Article

Trials for Alzheimer’s Drug Halted After Poor Results
New York Times

Johnson & Johnson and Pfizer announced on Monday that they were halting development of a closely watched Alzheimer’s drug after two clinical trials failed to show that it was effective in patients with mild to moderate forms of the disease. Late last month, results of a large clinical trial of the drug, called bapineuzumab, failed to show that patients — all of whom carried a particular gene that raises the risk of getting Alzheimer’s — improved either cognition or daily functioning compared with a placebo.